Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Xcite, ReNeuron, CPL Resources

Thu, 28th Jan 2010 11:25

Shares in Xcite Energy jumped after the oil group said its subsidiary Xcite Energy Resources has concluded an agreement with BP subsidiary BP Oil International to market and sell Xcite's crude oil from the Bentley field in the North Sea.ReNeuron group climbed after the stem cell developer said Phase 1 trials for its ReN001 stroke treatment should be given the green light soon following a favourable response to data provided to the UK Gene Therapy Advisory Committee.Irish recruitment group CPL Resources tumbled Thursday as it reported a big drop in gross profit and much lower revenue for the six months to 31 December.Gross profit fell 37% to €13m and profit before tax and an impairment charge of €4.5m in 2008 slumped to €2.4m from €6m. Revenue sank to €91.4m from €118.9m.Publishing Technology, which provides software and services to the publishing industry, says delays to project spend in both the UK and US because of the recession mean revenue and earnings before interest, tax, depreciation and amortisation (EBITDA) will be unchanged from the year before.But earnings before tax are expected to be 'significantly' better as 2009 contains no further amortisation of intangible assets or provisions for onerous leases.Product development software specialist Sopheon predicts revenues for the year ended 31 December 2009 will exceed £8m, although that's down from £9.3m in 2008.Chairman Barry Mence says a profitable fourth quarter shows that 'we reacted appropriately to balancing investment with cost containment'. 'Our current pipeline, coupled with our unique solution set and the continued maturing of our chosen market, gives me continued confidence in our quest to improve shareholder value.'Internet booth and WiFi hotspot provider Spectrum Interactive has completed the roll-out of WiFi services across the motorway service station estate of Moto Hospitality. 'This is an important contract for Spectrum, as it is first to bring Spectrum's WiFi service to the UK motorway services sector.Film finance provider and movie promoter Intandem has made a 'positive start' to 2010. It has completed one film, "The Kid", which it expects to show at the Berlin Flim Festival in February, and has four more films in post-production, all of which should be ready for the Cannes film festival.The s still in advanced negotiations to settle the £5.7m loan and expects to make a further announcement in due course.Asia-focused online advertising sales company Pixel Interactive is to lose a customer that provided a substantial proportion of its turnover in 2009. The company is in negotiations with the customer to minimise the impact on Pixel, but the change is likely to have a material impact on Pixel's revenue and profit forecasts for 2010.Online tech retailer Expansys cut losses sharply in the six months to October to just £162,000 against £1.73m. Revenues for the period were £20.4m (2008: £25.3m), but fell 6% on the six months to 30 April 2009. Pre-tax losses were £24,000 (2008: £1.1m). Chief executive Roger Butterworth has stepped down to pursue other business opportunities.Electronic displays group Densitron returned to profitability in the second half of 2009 and expects to return a small profit for the year as a whole.Advanced Medical Solutions says Cardinal Health, a major US healthcare services company, is marketing and distributing AMS's LiquiBand topical skin adhesive range in the US to hospitals, care centres, and surgeries.Hansard Global reports new business in Q2 2009/10 was 25% ahead of Q1 at £40.9m. The group had $1.16bn of Assets under Administration at 31 December 2009, up 15.6% since 30 June 2009. Policyholder cash flows have been strong through the period;
More News
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more
4 Apr 2019 10:32

ReNeuron Shares Rise On Positive Data From Blindness Treatment Trial

LONDON (Alliance News) - Shares rose in ReNeuron Group PLC on Thursday after it reported positive efficacy in a phase one/two clinical trial of its hRPC cell therapy candidate for treating in the

Read more
18 Mar 2019 11:42

ReNeuron Group Starts Dosing Of Second Cohort In hRPC Study

LONDON (Alliance News) - ReNeuron Group PLC on Monday said it started dosing of the second cohort of patients in a phase II study of its hRPC cell therapy candidate in the blindness-causing of in

Read more
18 Mar 2019 11:33

ReNeuron Group begins dosing second cohort in hRPC study

(Sharecast News) - Cell-based therapeutics company ReNeuron Group updated the market on progress with the ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more
20 Feb 2019 09:47

ReNeuron Reports Positive Preliminary Data In US Retinal Trial

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday reported "significant improvement in vision" in the trial of its hRPC cell therapy candidate for retinal disease.ReNeuron

Read more
20 Feb 2019 08:21

ReNeuron storms on 'exciting' eye disease trial success

(Sharecast News) - ReNeuron Group bounded upward on Wednesday after reporting that its cell-based therapy is showing signs that it can improve the sight of patients suffering from retinitis pigmentosa, which causes blindness.

Read more
31 Jan 2019 09:55

ReNeuron upbeat on data around ease of exosome manufacture

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that new data relating to the manufacturing scale-up of its GMP produced, CTX-derived exosomes was being presented at a US forum on the manufacture of cell and gene therapies.

Read more
24 Jan 2019 12:16

ReNeuron Group Reports First Enrolled Patient In Stroke Clinical Trial

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said it enrolled the first patient in its US Phase IIb clinical study of CTX stem cell therapy for stroke disability.The study is a 6

Read more
24 Jan 2019 09:46

First patient dosed in latest ReNeuron study of CTX cell therapy

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Thursday that the first patient has been treated in the US Phase IIb clinical study of its 'CTX' cell therapy candidate for stroke disability.

Read more
4 Jan 2019 07:59

ReNeuron Group to collaborate with unnamed US biopharmaceutical firm

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has signed a collaboration agreement with an unnamed US-based biopharmaceutical company to explore the use of its exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy, it announced on Friday.

Read more
14 Dec 2018 12:07

ReNeuron narrows losses as development programmes continue

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group issued its interim results for the six months ended 30 September on Friday, reporting a reduced loss for the period of £5.32m, from £9.57m year-on-year.

Read more
7 Dec 2018 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 10 December Photo-Me InternationalHalf Year ResultsHollywood Bowl GroupFull Year

Read more
18 Oct 2018 12:42

Reneuron's stem cell technology could produce cancer-combating cells

(Sharecast News) - New data from a study by Reneuron has encouraged the company that its stem cell technology could be adapted to specifically attack cancerous cells.

Read more
18 Oct 2018 10:54

ReNeuron Reports New Positive Data Relating To CTX Stem Cell Platform

LONDON (Alliance News) - ReNeuron Group PLC on Thursday said its CTX stem cell therapy candidate can be successfully re-programmed to a pluripotent state.Pluripotent state is an embryonic a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.